2019 ASCO Annual Meeting!
Session: Health Services Research, Clinical Informatics, and Quality of Care
Type: Poster Session
Time: Saturday June 1, 1:15 PM to 4:15 PM
Location: Hall A
Quality of life (QOL) in patients undergoing CAR-T therapy versus stem cell transplant (SCT).
Health Services Research, Clinical Informatics, and Quality of Care
2019 ASCO Annual Meeting
Poster Board Number:
Poster Session (Board #285)
J Clin Oncol 37, 2019 (suppl; abstr 6594)
Author(s): Surbhi Sidana, Amylou C. Dueck, Michelle Burtis, Joan M. Griffin, Gita Thanarajasingam, Rahma M. Warsame, Carrie A. Thompson, Andrea L. Cheville, Morie A. Gertz, Kathleen J. Yost, Angela Dispenzieri, Jose Villasboas Bisneto, Jonas Paludo, Stephen M. Ansell, S. Vincent Rajkumar, Nabila Nora Bennani, Patrick B. Johnston, Mustaqeem Ahmad Siddiqui, Yi Lin, Shaji Kumar; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ; Mayo Clinic, Health Sciences Research, Rochester, MN; Division of Hematology, Mayo Clinic, Rochester, MN
Background: Given the significant short-term adverse effects of CAR-T cell therapy, it is important to evaluate its impact on QOL of patients in addition to efficacy, compared with established forms of cellular therapy like SCT. Methods: QOL was evaluated prospectively in patients undergoing CAR-T therapy, autoSCT & alloSCT for hematologic malignancies. QOL was assessed with FACT-G at baseline, 2 weeks and monthly for 6 months thereafter. Functional well-being (FWB), physical WB (PWB) emotional WB (EWB) & social WB (SWB) and change over time were compared across groups. Results: 45 patients were recruited (CAR-T: 10; Auto SCT: 22; Allo SCT: 13) with follow up for 2 weeks & 1 month available for 23 &15 patients, respectively (Table). There was no statistically significant difference in baseline total QOL scores (p=0.13), though scores were lower in the alloSCT group (85,84,68). EWB &FWB were numerically higher in the CAR-T group, followed by autoSCT group. At 2 weeks, overall QOL decreased by only 2 points in CAR-T group vs. 22 & 18 points in auto & alloSCT groups (p=0.09). Change in PWB vs. baseline was less pronounced in the CAR-T group (-1, -9, -13, p=0.03). At 1 month, overall QOL was 6 points lower than baseline in CAR-T group vs. 3 and 14 points lower in auto & alloSCT groups, respectively (p=0.34). Importantly, PWB had at least returned to baseline in the CAR-T group. Conclusions: Preliminary data show that patients undergoing CAR-T cell therapy do not experience a more significant decline in QOL compared with auto & allo SCT, and may experience fewer physical side effects in the short-term. Accrual & follow-up are ongoing.
|Median age, years||62.5||62.2||61.4||0.9|
|FACT-G Baseline Median|
|Physical WB (0-28)||19||22||20||0.70|
|Social WB (0-28)||24||24.5||22||0.12|
|Emotional WB (0-24)||20||19||16||0.12|
|Functional WB (0-28)||20.5||18||14||0.09|
|Total FACTG (0-108)||85||84||68||0.13|
|QOL Change Week 2 vs. Baseline||N=7||N=10||N=6|
|QOL Change Month-1 vs. Baseline||N=5||N=5||N=5|